The Taiwan Stock Exchange announced that PET Pharm Biotech submitted its application for listing on the Innovative Board on the 24th. PET Pharm Biotech is the eighth company this year to apply for an Innovative Board listing. The lead underwriter for the listing application is Hong Yuan Securities.

Founded on October 3, 2011, PET Pharm Biotech is a nuclear medicine pharmaceutical company led by Chairman John Yang and General Manager Terry Lin. According to the summary of the public prospectus, the company has a paid-in capital of NT$572 million. Its main products include PIC/S GMP sterile preparations and molecular imaging drugs (radiopharmaceuticals), while the company is also engaged in new drug development.

In terms of financial performance, PET Pharm Biotech reported a pre-tax profit of NT$12.419 million in 2024, with earnings per share (EPS) of NT$0.36. Last year, the company’s operating revenue reached NT$130 million. Its product sales are entirely domestic, with 100% of revenue coming from the Taiwan market and no export business.

PET Pharm Biotech’s stock price has recently shown strong momentum, climbing along the 5-day and 10-day moving averages and maintaining a high trading range.

Resource: 核子醫學藥廠吉晟生技申請創新板上市 為今年第8家送件企業